The group’s principle activities include discovering and developing diagnostics for targeting cell-signaling pathway Nodes detected in well-defined cellular sub-populations from individual patients. The group’s diagnostic methods can be used for prognostic purposes including tracking disease progression, patient monitoring, and prediction of individual patient response to approved drugs and drug candidates in development. The group operates from United States.
